Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
Eileen Shiuan,Anupama Reddy,Stephanie O. Dudzinski,Aaron R. Lim,Ayaka Sugiura,Rachel Hongo,Kirsten Young, Xian-De Liu,Christof C. Smith,Jamye O'Neal,Kimberly B. Dahlman,Renee McAlister,Beiru Chen, Kristen Ruma,Nathan Roscoe,Jehovana Bender, Joolz Ward,Ju Young Kim,Christine Vaupel,Jennifer Bordeaux,Shridar Ganesan,Tina M. Mayer,Gregory M. Riedlinger,Benjamin G. Vincent,Nancy B. Davis,Scott M. Haake,Jeffrey C. Rathmell,Eric Jonasch,Brian I. Rini,W. Kimryn Rathmell,Kathryn E. Beckermann Cancers（2021）
Key words
renal cell carcinoma,PD-1,PD-L1,biomarkers,immune checkpoint inhibitors
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper